Wednesday, January 25, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

Radiation Biodosimetry High Throughput Tests

by Global Biodefense Staff
December 1, 2014
Arktis Radiation Detectors Awarded DARPA Contract

The Biomedical Advanced Research and Development Authority (BARDA) is seeking capability statements from businesses to provide verification, validation, regulatory approval, manufacturing and acquisition services for high throughput biodosimetry devices.

The Radiation Biodosimetry High Throughput (HT) Test is intended to be run in clinical laboratories and produce a quantitative estimate of the actual absorbed radation dose a person received from 0 to 10 Gy. The result will be used in conjunction with signs, symptoms, and hematology to give the health care provider additional information to help in treating individuals after a radiological or nuclear incident.

The typical symptoms of radiation exposure in humans (dose range of 0.5 to 10 Gy) include nausea, vomiting, diarrhea, and peripheral blood lymphocyte depletion. The duration of initial or prodromal symptoms and the latent phase of radiation syndrome is anywhere from 1 hours to 2 weeks.

Without appropriate medical care, the median lethal dose of radiation, the LD50/60 (the dose that kills 50% of the exposed population within 60 days after exposure), is estimated to be 4.5 Gy.  However, the likelihood of survival can be significantly increased with appropriate aggressive medical intervention and care.

For this effort, systems must be mature enough to enter into verification and validation activities consistent with FDA guidelines within the next year, with a minimum Technology Readiness Level of 6 at proposal submission.

Respondents must provide evidence that they have or have plans to achieve specified GMP instrument manufacturing capabilities, if the instrument being used for the assay is not currently commercially available.

Further details are available via Solicitation Number: CBRN-BAA-15-100-SOL-00010. The response deadline is Dec 15, 2014.

Tags: ASPRBARDABiodosimetryHHSRadiationRequest for Proposals

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
two soldiers are in head-to-toe hazmat suits with respirator masks while tending to a mannikin on a stretcher
CBRNE

Protection from Biothreats: DOD to Modernize Medical Countermeasures Development

January 10, 2023
Killing Anthrax More Quickly with Hot Air Decontamination
CBRNE

Killing Anthrax More Quickly with Hot Air Decontamination

January 4, 2023
New Material Helps Train First Responders on Biothreats
Biodetection

New Material Helps Train First Responders on Biothreats

January 4, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC